Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Nucleic Acid Based Gene Therapy Market Size from 2025 to 2034?
In recent times, the market size of nucleic acid based gene therapy has seen robust growth. The market, which was worth $0.81 billion in 2024, is estimated to increase to $0.88 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth during the historical period include better comprehension of human genetics, a rising demand for personalized medicine, expansion in the product pipeline of gene therapy, increased government backing for gene therapy, along with genetic disorders, and cancer therapy.
The market size of nucleic acid-based gene therapy is projected to witness substantial expansion in the upcoming years. It is anticipated to hit a benchmark of $1.3 billion in 2029 with a 10.3% compound annual growth rate (CAGR). The growth within this period can be attributed to increasing indications, enhanced funding, rising awareness and patient advocacy. In addition, there is an increase in investment for the research and development of gene therapy and broadened areas of gene therapy applications for rare diseases. The key trends during this forecast period encompass ex vivo gene editing, progress in in vivo gene editing, combination therapies, precision delivery systems, and gene editing aimed at rare diseases, along with non-viral vectors.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Nucleic Acid Based Gene Therapy Market?
The increase in financial backing from both government and corporate entities is predicted to escalate the demand for nucleic acid-based gene therapy. Nucleic acid therapeutics, considered analogs of organic acids or proteins crucial for genetic manifestation, form part of a new wave of treatment. Traditional methods have been unable to discover cures for conditions like cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. The success of these innovative drugs depends significantly on genetic profiling and molecular target identification. Nucleic acid medicines, which pinpoint the genetic origin of diseases, have the potential to provide permanent solutions. The escalating financial aid from governments and businesses in the gene therapy market is anticipated to boost the demand for nucleic acid-based gene therapies. For example, the National Institute of Health (NIH) stated in August 2022 that it plans to invest $34 million annually for the next five years into HIV treatment research. This government support is expected to stimulate the growth of the nucleic acid based gene therapy market.
Which Key Market Segments Comprise the Nucleic Acid Based Gene Therapy Market and Drive Its Revenue Growth?
The nucleic acid based gene therapymarket covered in this report is segmented –
1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies
2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases
3) By End User: Hospitals And Clinics, Academic And Research Institutes
Subsegments:
1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)
2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies
3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)
4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs
5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes
6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers
7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp
Which Areas Are Leading Regions in the Nucleic Acid Based Gene Therapy Market Expansion Across the Globe?
North America was the largest region in the nucleic acid-based gene therapy market in 2024. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
View the full report here:
How Is the Nucleic Acid Based Gene Therapy Market Conceptually Defined?
Nucleic acid-based gene therapy is a medical treatment approach that uses nucleic acids (such as DNA or RNA) to modify or manipulate genes within a patient’s cells to treat or prevent diseases. This therapy aims to address the root cause of a disease at the genetic level by directly intervening in the genetic material that leads to the malfunctioning of cells.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2820
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model